{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T17:08:24Z","timestamp":1773162504929,"version":"3.50.1"},"reference-count":0,"publisher":"Esmon Publicidad, SA","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Investig Allergol Clin Immunol"],"published-print":{"date-parts":[[2024,12,9]]},"abstract":"<jats:p>Background: Allergic conjunctivitis is the most common type of ocular allergy.\nObjective: The objective of this study was to evaluate the efficacy of a new once-daily, preservative-free, bilastine 0.6% eye drop formulation for the treatment of allergic conjunctivitis.\nMethods: Two double-masked, vehicle-controlled, clinical studies (a phase 2 dose-ranging study and a phase 3 efficacy study) were conducted to assess the efficacy of bilastine ophthalmic solution for treatment of the signs and symptoms of allergic conjunctivitis. Both studies used the Ora-CAC\u00ae Conjunctival Allergen Challenge (CAC) model to enable observation of allergic responses under controlled conditions. Each study was analyzed separately and then combined to create an integrated data set.\nResults: Efficacy was achieved for the primary efficacy endpoint of ocular itching with 3 bilastine concentrations (0.2%, 0.4%, and 0.6%) at 15 minutes and 8 hours after instillation. Bilastine 0.6% ophthalmic solution was also efficacious at 16 hours after instillation. Bilastine 0.6% ophthalmic solution demonstrated noninferiority to ketotifen 0.025% at the onset of action. According to the integrated data set, differences between vehicle and bilastine 0.6% after instillation were significant at all time points both at onset (15 minutes) and after a prolonged duration (16 hours).\nConclusion: This multitrial assessment suggests that bilastine 0.6% ophthalmic solution is efficacious for the treatment of the signs and symptoms of allergic conjunctivitis, with a rapid onset and prolonged duration of action, and has a favorable safety profile. The added convenience of once-daily dosing may contribute to adherence and improve quality of life.<\/jats:p>","DOI":"10.18176\/jiaci.0940","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T11:31:31Z","timestamp":1695295891000},"page":"385-394","source":"Crossref","is-referenced-by-count":4,"title":["Bilastine 0.6% Preservative-Free Eye Drops as an Effective Once-Daily Treatment for the Signs and Symptoms of Allergic Conjunctivitis: A Pooled Analysis of 2 Randomized Clinical Trials"],"prefix":"10.18176","volume":"34","author":[{"given":"PJ","family":"Gomes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JB","family":"Ciolino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P","family":"Arranz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A","family":"Gonzalo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N","family":"Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7491","published-online":{"date-parts":[[2024,12,10]]},"container-title":["Journal of Investigational Allergy and Clinical Immunology"],"original-title":["english"],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T11:12:27Z","timestamp":1733829147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jiaci.org\/summary\/vol34-issue6-num2972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,9]]},"references-count":0,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,12,10]]},"published-print":{"date-parts":[[2024,12,9]]}},"URL":"https:\/\/doi.org\/10.18176\/jiaci.0940","relation":{},"ISSN":["1018-9068"],"issn-type":[{"value":"1018-9068","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,9]]}}}